Literature DB >> 7525998

Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues.

D W Cohen1, R Simak, W R Fair, J Melamed, H I Scher, C Cordon-Cardo.   

Abstract

Cells respond to certain soluble factors that bind to cell surface receptors possessing intrinsic tyrosine kinase activity. Overexpression of these molecules has been associated with tumor progression. Enhanced prostatic cancer cell growth in vitro has been reported in the presence of certain growth factors. To characterize the patterns of expression of the epidermal growth factor receptor (EGFr) and transforming growth factor-alpha (TGF alpha), we studied tissue from 107 prostate specimens using immunohistochemistry. We observed that epithelial cells of normal (n = 4) and benign prostatic (n = 56) tissues express EGFr but were unreactive for TGF alpha, while stroma cells in these tissues express TGF alpha but not EGFr. However, coexpression of EGFr and TGF alpha was identified in 22 of 46 prostatic adenocarcinomas studied. These results suggest that the major mode of action of EGFr/TGF alpha in normal and benign prostate is that of a paracrine or juxtacrine loop, the ligand being expressed in the stroma cells and the receptor in the epithelial cells. Since a subset of prostatic carcinomas coexpressed the ligand and the receptor in their tumor cells, it is suggested that an independent autocrine signaling mechanism may occur and grant a selective advantage for the growth of prostate cancers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525998     DOI: 10.1016/s0022-5347(17)32335-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Variability of immunohistochemical reactivity on stored paraffin slides.

Authors:  E O Olapade-Olaopa; E H MacKay; F K Habib
Journal:  J Clin Pathol       Date:  1998-12       Impact factor: 3.411

2.  Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial.

Authors:  Xiaotian Zhang; Jianming Xu; Huilong Liu; Lin Yang; Jun Liang; Nong Xu; Yuxian Bai; Jiejun Wang; Lin Shen
Journal:  Med Oncol       Date:  2014-09-19       Impact factor: 3.064

Review 3.  The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.

Authors:  Rebecca G Pomerantz; Jennifer Rubin Grandis
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

4.  Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.

Authors:  Glenn Liu; Yu-Hui Chen; Jill Kolesar; Wei Huang; Robert Dipaola; Michael Pins; Michael Carducci; Mark Stein; Glenn J Bubley; George Wilding
Journal:  Urol Oncol       Date:  2011-07-23       Impact factor: 3.498

Review 5.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

6.  Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.

Authors:  Carlo Vicentini; Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; Angelo Marronaro; Mauro Bologna
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-04       Impact factor: 4.553

7.  Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.

Authors:  Derek P Simon; Sivan Vadakkadath Meethal; Andrea C Wilson; Miguel J Gallego; Stephanie L Weinecke; Erin Bruce; Patrick F Lyons; Ryan J Haasl; Richard L Bowen; Craig S Atwood
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

8.  Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer.

Authors:  E O Olapade-Olaopa; D K Moscatello; E H MacKay; T Horsburgh; D P Sandhu; T R Terry; A J Wong; F K Habib
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

9.  Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells.

Authors:  Alpna Tyagi; Yogesh Sharma; Chapla Agarwal; Rajesh Agarwal
Journal:  Pharm Res       Date:  2008-02-06       Impact factor: 4.580

10.  Defined medium for normal adult human prostatic stromal cells.

Authors:  D M Peehl; R G Sellers; S T Wong
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998 Jul-Aug       Impact factor: 2.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.